The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.

The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

Infosys has agreed to pay $250m for sales services provider Simplus, which had raised more than $40m in funding from backers including Salesforce Ventures.

Columbia's drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Salesforce-backed sales motivation software developer LevelEleven is merging with fellow Ascent Group portfolio company Geopointe.

Affordable e-commerce platform Brandless is closing its doors, having been valued at $500m in a round backed by SoftBank Vision Fund and GV.

Keppel has exited data centre operator Etix Everywhere, which has been acquired as part of Vantage Data Centers' $2bn European expansion.

Wipro Ventures was given an exit from email security software developer Emailage, which was acquired by LexisNexis Risk Solutions. The sizeable exit is part of the wider cybersecurity space, which has received much attention by corporates over the past decade.

The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.